Longevity Biomedical waives $30M minimum cash condition for Denali merger

Semnur Pharmaceuticals, Inc.

Longevity irrevocably waived the $30M minimum cash condition in the merger agreement with Denali Capital Acquisition Corp.
Waiver effective August 29, 2023; removes a key closing condition for the business combination.
Merger agreement originally signed Jan 25, 2023, amended April 11, 2023.
Parties include Denali, Longevity, Holdco, Merger Subs, and seller representative Bradford A. Zakes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.